← Leaderboards
Christopher J Sweeney
Indiana Univ-Purdue Univ At Indianapolis
$4,398,891
Attributed
$4,398,891
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $635.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,398,891 · 15
By mechanism
R01$4,013,482 · 2
R03$166,312 · 1
U54$156,790 · 1
M01$62,307 · 11
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Stephen D Hall$1,925,382
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorAftercareSourcePathway InteractionsResistanceMalignant NeoplasmsMutationSamplingLeadMalignant Neoplasm Of ProstateDocetaxelAbirateroneLocalized DiseaseCessation Of LifeClinical TrialsMetastatic Prostate CancerGenesExomeEastern Cooperative Oncology GroupGenomicsDisease ResistanceExome SequencingInsightBiochemical
Grant awards (25)
Cancer Detection & Diagnosis Research-2022-Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer$258,777
R01 · FY2025 · CA · contact PI
Cancer Detection & Diagnosis Research-2022-Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer$121,318
R01 · FY2025 · CA · contact PI
Cancer Detection & Diagnosis Research-2022-Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer$367,841
R01 · FY2023 · CA · contact PI
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer$513,517
R01 · FY2022 · CA · contact PI
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer$577,920
R01 · FY2021 · CA · contact PI
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer$616,230
R01 · FY2020 · CA · contact PI
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer$519,293
R01 · FY2018 · CA · contact PI
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer$481,793
R01 · FY2017 · CA · contact PI
Pilot Project 1: The Use of a Zebrafish Germ Cell Tumor Mutant to Identify Putative Genetic Mutation Drivers in Human Testicular Germ Cell Tumors$78,063
U54 · FY2017 · CA · contact PI
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer$556,793
R01 · FY2016 · CA · contact PI
Pilot Project 1: The Use of a Zebrafish Germ Cell Tumor Mutant to Identify Putative Genetic Mutation Drivers in Human Testicular Germ Cell Tumors$78,727
U54 · FY2016 · CA · contact PI
Evaluating a parthenolide analogue as a new bladder and kidney cancer therapy$83,156
R03 · FY2012 · CA · contact PI
Evaluating a parthenolide analogue as a new bladder and kidney cancer therapy$83,156
R03 · FY2011 · CA · contact PI
A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF CHEMOTHERAPEUTIC$1,047
M01 · FY2008 · RR · contact PI
PHASE I, PHARMACOKINETIC, PHARMACODYNAMIC TRIAL OF PTK787 AND PACLITAXEL IN C$1,003
M01 · FY2008 · RR · contact PI
A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF CHEMOTHERAPEUTIC$12,320
M01 · FY2007 · RR · contact PI
PHASE I, PHARMACOKINETIC, PHARMACODYNAMIC TRIAL OF PTK787 AND PACLITAXEL IN C$11,807
M01 · FY2007 · RR · contact PI
A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF CHEMOTHERAPEUTIC$13,737
M01 · FY2006 · RR · contact PI
PHASE I, PHARMACOKINETIC, PHARMACODYNAMIC TRIAL OF PTK787 AND PACLITAXEL IN C$7,272
M01 · FY2006 · RR · contact PI
PHASE I DOSE ESCALATION STUDY TO DETERMINE THE SAFETY,PHARMACOKINETICS AND$2,626
M01 · FY2006 · RR · contact PI
OSI-774 IN COMBO W/WEEKLY DOCETAXEL IN PTS W/TAXANE NAIVE MALIGNANCIES$808
M01 · FY2006 · RR · contact PI
A PHASE I STUDY OF OSI-461 IN COMBINATION WITH MITOXANTRONE (NOVANTRONE ) IN$202
M01 · FY2006 · RR · contact PI
A PHASE 1 SAFETY AND PHARMACOKINETIC STUDY OF SU011248 AND CAPECITABINE IN PA$202
M01 · FY2006 · RR · contact PI
OSI-774 IN COMBO W/WEEKLY DOCETAXEL IN PTS W/TAXANE NAIVE MALIGNANCIES$5,302
M01 · FY2005 · RR
OSI-774 in Combo w/Weekly Docetaxel in Pts w/Taxane Naive Malignancies$5,981
M01 · FY2004 · RR